Skip to main content

Glossary and FAQ

Explore key terms about Fagron and the pharmaceutical industry, and answers to frequently asked questions.

Pharmaceutical industry

Term Definition
503A
Compounding pharmacy that delivers personalized medication to patients on a script-by-script basis
503B
Large facility that produces compounding medication to hospitals and clinics and produces in bulk
CAPA
Corrective and Preventive Actions
API
Active Pharmaceutical Ingredient
Excipients
Functional ingredients used in compounding formulations
CADE
Conselho Administrativo de Defesa Econômica – Brazil’s antitrust authority
BHRT
Bioidentical Hormone Replacement Therapies - personalized supplementation therapies designed to optimize hormone levels as part of a health and wellness approach focused on prevention
Form 483
Observation letter from FDA following an inspection, naming articles where the inspection has detected breaches
GMP
Good Manufacturing Practice – standard required to manufacture medication to ensure quality, safety and efficacy
cGMP
Current Good Manufacturing Practice – manufacturers use up-to-date technologies and systems
IV
Intravenous
OTC
Over the counter – it can be purchased without a prescription from a doctor
Clean room
Where compounded medicine is produced and raw materials are repackaged
Out of pocket
Medication that is not subject to be reimbursed to the patient
CMO
Contract Manufacturing Organization
GLP-1
Glucagon-like peptide-1

Frequently Asked Questions

Information on this page was most recently updated on 15 April  2026.